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Background: This open-label, randomized study evaluated efficacy and safety of artemether-lumefantrine (AL) and
dihydroartemisinin-piperaquine (DP) in treatment of uncomplicated falciparum malaria in children below five years of age,
to build evidence on use of AL as first-line treatment and DP as second-line treatment in Kenya.
Methods: A total of 454 children aged six to 59 months with uncomplicated falciparum malaria were randomized (1:1) to
receive AL dispersible or DP paediatric tablets and followed up for 42 days. Primary efficacy variable was corrected
adequate clinical and parasitological response (ACPR) rate on day 28. Secondary variables included corrected (day 14,
28 and 42), uncorrected (day 3, 14, 28 and 42) cure rates, parasitological failure at days 3, 14 and 42. Acceptability and
tolerability of both drugs were assessed by caregiver questionnaire.
Results: On day 28, corrected ACPR rates for AL dispersible and DP paediatric were 97.8% (95% CI: 94.9-99.3) and 99.1%
(95% CI: 96.8-99.9), respectively, in intention-to-treat population, with no significant treatment differences noted between
AL dispersible and DP paediatric arms. Additionally, no significant differences were observed for PCR corrected cure rates
on days 14 and ACPR on day 42 for AL dispersible (100%; 96.8%) and DP paediatric (100%; 98.7%). Similarly, for PCR
uncorrected cure rates, no significant differences were seen on days 3, 14, 28, and 42 for AL dispersible (99.1%; 98.7%;
81.1%; 67.8%) and DP paediatric (100%; 100%; 87.7%; 70.5%). Parasite clearance was rapid, with approximately 90% clearance
achieved in 40 hours in both treatment arms. Incidence of adverse events was related to underlying disease; malaria being
reported in both treatment arms. One serious adverse event was noted in AL dispersible (0.42%) arm, not related to study
drug. Adherence to treatment regimen was higher for children treated with AL dispersible (93.6%) compared to DP
paediatric (85.6%). Acceptability of AL dispersible regimen was assessed as being significantly better than DP paediatric.
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Conclusions: AL and DP were both efficacious and well tolerated, and had similar effects at day 42 on risk of recurrent
malaria. No signs of Plasmodium falciparum tolerance to artemisinins were noted.
Trial registration: PACTR201111000316370.
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Malaria continues to be a major health problem worldwide,
with an estimated 216 million cases in 2010, approximately
174 million of which were in the African region [1]. Chil-
dren less than five years of age are at increased risk of Plas-
modium falciparum malaria, with a reported 86% mortality
rate globally [1]. Artemisinin-based combination therapy
(ACT) is recommended as the first-line treatment for un-
complicated P. falciparum malaria by the World Health
Organization (WHO) [2], over chloroquine and sulpha
drugs worldwide. Multidrug resistance has been reported
for monotherapy (for example artemisinin [3-5]) and some
of the available combination chemotherapy (for example,
sulphadoxine/sulphalene-pyrimethamine [6]) used for mal-
aria. Treatment with ACT is known to improve cure rates,
results in rapid parasite clearance [2,7] and reduces gam-
etocyte carriage resulting in a decrease in parasite transmis-
sion [2,8-10].
Artemether-lumefantrine (AL, Coartem®, Novartis
Pharma AG) is a first fixed-dose ACT, which meets the
WHO prequalification criteria for efficacy, safety and
quality, and is indicated for the treatment of uncompli-
cated falciparum malaria, or mixed infections including
P. falciparum in adults, children, and infants (>5 kg
body weight). Since the prequalification of Coartem®,
other AL generics have been prequalified by WHO. In
clinical studies, AL demonstrated consistent 28-day
polymerase chain reaction (PCR)-corrected cure rates of
more than 95% in adult and paediatric populations with
a favourable safety and tolerability profile [11]. With
rapid parasite clearance and gametocyte reduction also
being reported [11], the widespread adoption of AL has
led to a significant contribution in the reduction of
malaria burden in Sub-Saharan Africa [12]. Since the
Kenyan Ministry of Health introduced AL as the first-
line treatment for uncomplicated falciparum malaria in
2006, there has been a notable reduction in child mor-
tality rates [13]. Novartis launched the paediatric formu-
lation of AL (AL dispersible) in 2009, developed jointly
with Medicines for Malaria Venture (MMV). It is a
sweet-tasting and easy-to-administer tablet which is now
approved in over 40 countries. AL dispersible has proven
in clinical trials to be as well tolerated and as effective as
regular AL tablets [14,15]. Moreover, it has been shown
that standard African diets (generally consisting of a
carbohydrate staple supplemented by pulses, nuts, meator fish and fat from oil crops or from vegetables or
plants) and milk are adequate to ensure AL efficacy
[16]. However, AL is associated with a high risk of re-
infection soon after therapy in high-transmission
areas [17].
Dihydroartemisinin-piperaquine (DP: Duo-cotecxin®,
Holley-Cotec Pharmaceuticals) is an ACT that is admi-
nistered as a single daily dose over three days and has
been shown to be well tolerated and highly effective
against falciparum malaria [18]. In a previous compara-
tive assessment, DP has been proven to be as efficacious
and safe as AL in the treatment of uncomplicated falcip-
arum malaria in Zambian children less than five years of
age. DP has been suggested for use as a rescue and/or al-
ternative treatment to AL, or as second-line treatment
following treatment failure with the initial treatment
[19]. The Kenyan Ministry of Health adopted DP as
second-line treatment in 2009.
To further build on the evidence from earlier studies
that used AL as a first-line and DP as second-line treat-
ment, this study evaluated the efficacy and safety of AL
dispersible vs DP paediatric in Kenyan children less than
five years of age for the treatment of uncomplicated fal-
ciparum malaria.
Methods
This was an open-label, randomized, single-centre study
(Trial registration number: PACTR201111000316370).
The protocol was approved by the Kenya Medical Re-
search Institute Ethics Review Committee. The study
was conducted in accordance with the Declaration of
Helsinki (2002), Good Clinical Practices guidelines set
up by the International Conference on Harmonization
[20], and local applicable laws and regulations.
Patients
Children aged six to 59 months (inclusive), weighing 5 kg
or more with fever ≥37.5°C (axillary), who presented to
the Ombeyi Dispensary with probable clinical malaria,
mono-infection with P. falciparum at an asexual parasite
density of 1,000-200,000 parasites/μL, and who were able
to take drug orally, were eligible for enrolment in the
study. Patients were excluded if they had severe and/or
complicated malaria [21], including severe anaemia
(haemoglobin (Hb) ≤5 g/dL), experienced two or more
seizures in the previous 24 hours and hyperparasitaemia
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requiring hospitalization. Patients who had concomitant
infections/disease at the time of presentation, with past or
present history of chronic illnesses or any other under-
lying illness that would compromise the diagnosis and
evaluation of the response to the study drug, with a his-
tory of allergy to artemisinin, lumefantrine or piperaquine
were excluded. Patients undergoing full treatment with
other anti-malarial drugs within the previous 14 days were
also excluded. Eligible patients were enrolled after the
parent/guardian signed the written informed consent.
Study design
The study comprised a three-day treatment period (day 1
taken as the first day of treatment) and 42-day follow-up.
Eligible patients were randomized to one of the two
treatment arms (1:1) to receive either AL dispersible
(six doses/three days) or DP paediatric (three doses/three
days). Patients in the AL dispersible arm with body weight
5–14 kg received one tablet (artemether 20 mg, lumefan-
trine 120 mg) per dose, and 15–24 kg received two tablets
per dose. Patients in the DP paediatric arm received the
standard dosage of 2.25 mg/kg and 18 mg/kg per dose of
dihydroartemisinin and piperaquine, respectively, rounded
up to the nearest half tablet. The drugs were dispersed in
a small volume of water or milk and administered by the
parents/caregivers under the observation of the study
personnel. If there was vomiting within 30 minutes of the
dose then the child was re-dosed and if the child vomited
the replacement dose, he/she was dropped from the study.
All the drug administration occurred in an inpatient set-
ting. Children who developed severe malaria were treated
with quinine as per the national guidelines.
Children were admitted to hospital for the first three days
for observed treatment and close monitoring. They were
evaluated daily in the ward and eight-hourly blood slides
were performed until two consecutive negative blood
smears for asexual falciparum malaria were obtained. Chil-
dren were discharged after they had a negative slide and
were clinically stable. At discharge, the parent/caregiver
completed a questionnaire on the treatment acceptability,
and the children were followed up on days 7, 14, 28, 42 and
any other day the child was unwell. During the visits, a
blood slide was analysed for parasite quantification; blood
was collected for a complete blood count (CBC) and a filter
paper sample for genotyping in case of parasite re-
appearance; physical examination was performed and vital
signs, axillary temperature were recorded. Adverse events
(AEs) and serious adverse events (SAEs) were recorded and
monitored throughout the study.
Assessments
The primary efficacy assessment included patients with
PCR-corrected parasitaemia by day 28, i e, patients withan adequate clinical and parasitological response
(ACPR). According to the WHO definition [22], ACPR
is the absence of parasitaemia on day 28 or day 42
irrespective of axillary temperature, without previously
meeting any of the early treatment failure (ETF), late
treatment failure (LTF) or late parasitological failure
(LPF) criteria. As per the WHO definition [22], ETF is
development of danger signs of malaria or severe ma-
laria on post treatment days 0, 1, 2 or 3, with evidence
that the patient is symptomatic and parasitaemic to a
greater degree than the value recorded at entry to the
trial on day 2; parasitaemic on day 3 greater than 25% of
the value recorded on entry to the trial and with axillary
temperature ≥37.5°C. LTF is development of danger
signs or severe malaria between post-treatment days 4 to
14 inclusive when: a) the patient has not previously met the
criteria for ETF and, b) PCR analysis of markers including
merozoite surface protein (MSP)-1, MSP-2 and glutamate-
rich protein (GLURP) suggests that the parasites are un-
likely to be a new infection, with evidence that the patient
is symptomatic and any level of P. falciparum parasitaemia
on any day between 4, 28 or day 42, inclusive with axillary
temperature ≥37.5°C in patients not meeting ETF cri-
teria earlier. LPF is presence of parasitaemia on any
day between day 7 and day 28 (or day 42) with axil-
lary temperature <37.5°C in patients who did not pre-
viously meet any of the criteria of ETF or late clinical
failure.
The secondary efficacy and safety assessments included
parasitological failure at days 3, 14 and 42, (defined as pre-
sence or absence of parasitaemia on assessment), deter-
mination of the level of adherence, ease of use, acceptability
and adverse events (serious and non-serious) reported as
an indicator of safety for both drugs among patients en-
rolled in the study.
Safety assessments included recording of adverse
events (AEs, by system organ class and preferred terms),
serious adverse events (SAEs), treatment emergent
serious and non-serious adverse events (AEs occurring
between day 1 and 35 of treatment period or AEs with
unknown onset dates), and collection of clinical labora-
tory data for haematology and blood chemistry. Accor-
ding to the ICH guidelines [20], AEs are defined as any
untoward medical occurrences in a patient administered
a pharmaceutical product and which does not necessa-
rily have a causal relationship to the treatment. SAEs
are untoward medical occurances that at any dose,
result in death, are life threatening, require hos-
pitalization, prolongation of existing hospitalization or
result in persistant, and significant disability, or is
a congenital anomaly/birth defect. During the study
period the area was under indoor residual spraying
(IRS) for malaria as a pilot district in the deployment
of IRS in high transmission areas by the Division of
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Sanitation, Kenya.
Statistical analysis
In this non-inferiority trial, it was estimated that 193 pa-
tients per arm were needed to complete the study, assu-
ming that at day 28, the efficacies of AL dispersible and DP
paediatric were 90%, with a power of 80%, and a two-sided
significance level of 5%. Allowing for a 10% dropout rate, it
was calculated that 233 patients per arm (426 in total) had
to be randomized. Baseline data were summarized by con-
tinuous variables using mean (standard deviation (SD)) if
normally distributed, tested using t-test or ANOVA where
appropriate or using median and inter-quartile range and
non-parametric testing if not normally distributed.
The efficacy variables were analysed on the intent-to-
treat (ITT) and per protocol (PP) population. The ITT
population included all patients who received at least
one dose of study drug. Patients with a major protocol
deviation were included in the analyses. The PP popula-
tion excluded patients with predefined protocol viola-
tions and included patients who completed all visits as
specified in the protocol; had no major protocol viola-
tion with regards to inclusion/exclusion criteria; did not
take any prohibited concomitant medications during the
treatment period. Patients who were withdrawn from
the study due to an AE or lack of efficacy, or who were
considered a treatment failure, were included in the PP
population.
For the primary efficacy variable, the treatment effect
was the difference in efficacy between the two arms at
day 28. Missing data was analysed by using completeFigure 1 Patient flow.case analysis wherein patients with missing efficacy data
were excluded from the analysis. For secondary efficacy
analyses, the treatment effect was the difference in effi-
cacy between the two treatment arms at days 3, 14 and
42. In the analyses of safety data, the biological param-
eter analysis by treatment regimen was assessed by the
mean (95% confidence interval (CI)) change from base-
line on day 28. The mean (SD) parameter value at day
28 was presented for each arm. Formal testing for a dif-
ference between treatments was done using ANOVA
comparing average day 28 values, adjusting for baseline
values. Adverse events (both serious and non-serious)
have been tabulated using preferred terms by treatment
arm in Medical MeDRA V. 12. Failure rate has also been
presented based on parasite density at baseline.
Results
This study was conducted at Ombeyi dispensary in Nyando
District, Kenya. The first patient was enrolled on 5 March,
2010 and the last patient completed the study on 30
November, 2011.
Patient disposition, demographics, and baseline
characteristics
A total of 1979 children were screened of which 1525
were screening failures, with most being non-malaria
cases, low parasite density, mixed species malaria infec-
tions and consent refusal (Figure 1). In total, 454 pa-
tients were randomized (1:1) to the AL dispersible or DP
paediatric treatment arms and 448 (98.6%) completed
the study. Two patients receiving DP and four patients
receiving AL dispersible treatment were withdrawn from
Table 1 Patient demographics and baseline characteristics
Characteristics AL dispersible (n = 227) DP paediatric (n = 227) p value*
Age (months) 29.6 (15.2) 32.0 (14.9) 0.094
Weight (kg) 12.2 (3.2) 12.3 (3.2) 0.709
Temperature (°C) 38.3 (1.0) 38.3 (2.1) 0.949
Parasite density (/μL), mean (95% CI)† 38,202.2 (32,180.0 to 45,351.3) 38,545.7 (32,615.8 to 45,553.8) 0.941‡
Haemoglobin (g/dL) 9.2 (1.9) 9.4 (2.0) 0.293
White blood cells (x103/μL) 9.9 (4.5) 9.5 (3.8) 0.258
Platelets (x103/μL) 134.8 (66.1) 134.9 (67.1) 0.988
Red blood cells (x106/μL) 3.7 (0.9) 3.7 (0.8) 0.764
Neutrophils (%) 41.0 (17.5) 43.1 (17.8) 0.203
Lymphocytes (%) 50.6 (17.2) 48.4 (17.5) 0.182
Monocytes (%) 7.4 (3.0) 7.6 (4.9) 0.559
Data are mean (±SD) unless otherwise specified. AL: Artemether-lumefantrine; DP: dihydroartemisinin-piperaquine; *p value from t-test or Mann–Whitney test;
†Geometric mean with its 95% CI; ‡p value from t-test on the log parasite density.
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to tolerate the medication (vomiting; Figure 1). The
baseline demographics and clinical characteristics were
similar between the two arms (Table 1).
The corrected ACPR rates in the ITT population were
97.8% (95% CI 94.9-99.3) and 99.1% (95% CI 96.8-99.9)
for AL dispersible and DP paediatric, respectively, on
day 28 (treatment difference 1.3%, 95% CI: -1.0-3.6%;Figure 2 PCR-corrected and uncorrected cure rates in ITT population.
rates in ITT population. AL: Artemeter-lumefantrine dispersible; DP: dihydrop = 0.258; Figure 2a). No significant treatment diffe-
rences were observed for the corrected ACPR rates on
days 14 and 42 between the AL dispersible and the DP
paediatric arm in the IIT population (Figure 2a). For the
uncorrected cure rates, no significant differences were
seen on days 3, 14 and 28 and 42 between the AL dis-
persible and the DP paediatric arm (p > 0.05) for all
comparisons (Figure 2b). Similar results were obtaineda) PCR-corrected cure rates in ITT population. b) PCR-uncorrected cure
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Figure 3 Parasite clearance time following ACT treatment for malaria.
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ACPR rates (Figure 2).
Parasite clearance was rapid, with 90% clearance
achieved in 40 hours in both treatment arms (Figure 3),
and 50% parasite clearance was achieved within 24 hours
in both treatment arms. Treatment failure at day 28 was
unaffected by baseline parasite load for both AL disper-
sible and DP paediatric arms. The treatment failure rate
for AL dispersible and DP paediatric was comparable for
parasite densities of <50,000/μL and >50,000/μL (23 vs
20 for AL dispersible, p = 0.634; 12 vs 14 for DP paedia-
tric; p = 0.959; Table 2). Similar results were observed for
parasite rates <100,000 and >100,000 (31 vs 12 for AL;
p = 0.901; 23 vs 5 for DP; p = 0.379).
Safety
The overall incidence of AEs was 65.5% (156/238) and
67.5% (156/231) in the AL dispersible and DP arms, re-
spectively (Table 3). The most frequently reported AEs
were related to the underlying disease; malaria was re-
ported in both treatment arms (25.6% and 18.2% in the
AL dispersible and DP paediatric arms, respectively).
Cough was predominant in both treatment arms (15.5%
and 17.3% in the AL dispersible and DP paediatric arms,
respectively). One patient in the AL dispersible arm had
a SAE, severe malaria, not considered by the investigator
to be related to the study drug. No deaths were reported
during the study. Both treatments were generally well
tolerated. The safety profile was comparable for ALTable 2 Effect of parasite load at baseline on failure: day 28
Parasite load at baseline Failure at day 28 p-value*
≤50,000 (n = 223) 37 (16.6%) 0.796
>50,000 (n = 219) 34 (15.5%)
≤100,000 (n = 328) 54 (16.5%) 0.768
>100,000 (n = 114) 17 (14.9%)
*p-value from chi-square/fishers exact test.dispersible and DP paediatric arms with regard to bio-
logical parameters including haemoglobin, white blood
cells, platelets, red blood cells (RBCs), lymphocytes and
monocytes (Table 4).
Tolarability and acceptability assessed by caregiver
questionnaire, including general questions with respect
to preferred paediatric formulations, are presented in
Table 5. Adherence to treatment regimen was higher in
the AL dispersible arm (93.6%) compared to DP paedia-
tric (85.6%). Among the 126 patients randomized to re-
ceive AL dispersible, 103 (82%) considered it ‘simple’ or
‘very simple’ to use compared with 83 (67%) in the DP
paediatric arm. The taste of AL dispersible was ‘liked’ or
‘liked very much’ by 72% of respondents, compared with
56% for DP paediatric. The majority in both groups took
the drug with a meal (AL dispersible = 94.4%; DP paedia-
tric = 89.4%), and preferred water to dissolve the tablets
(AL dispersible = 94.4%; DP paediatric = 89.4%). In ge-
neral, caregivers preferred the dispersible tablet formula-
tion (drug given as tablet dissolved in a small volume of
water/milk) as compared to a syrup formulation (AL
dispersible = 76.8% vs 16.8%; DP paediatric = 62.3% vs
29.5%).
Discussion
In the present study, AL dispersible and DP paediatric
were found to be highly efficacious for the treatment of
uncomplicated falciparum malaria in Kenyan children
less than five years of age. The 28-day corrected ACPRAL dispersible p-value* DP dispersible p-value*
23 (20.5%) 0.735 14 (12.6%) 0.959
20 (18.2%) 14 (12.6%)
31 (19.1%) 0.851 23 (13.9%) 0.484
12 (20.0%) 5 (9.3%)
Table 3 Most frequent adverse events (≥2% in any
treatment arm)




Patients with at least one adverse
event
156 (65.54) 156 (67.53)
Malaria 61 (25.63) 42 (18.18)
Cough 37 (15.55) 40 (17.32)
Anaemia 10 (4.20) 8 (3.46)
Fever 7 (2.94) 14 (6.06)
Tinea capitis 10 (4.20) 12 (5.19)
Rhinitis 4 (1.68) 13 (5.63)
Gastroenteritis 9 (3.78) 5 (2.16)
Loss of appetite 3 (1.26) 6 (2.59)
Otitis media 7 (2.94) 5 (2.16)
AL: Artemether-lumefantrine; DP: dihydroartemisinin-piperaquine.
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nificantly different to those seen in patients receiving DP
paediatric. The corrected ACPR rates were similar to
those previously reported in Kenya and other parts of
Africa [19,22]. This shows that despite scaled-up use
of AL dispersible in Kenya, the AL is still efficacious
as first-line treatment. In contrast to earlier findings
[19,23,24], there were no significant treatment diffe-
rences noted in uncorrected ACPR rates between the AL
dispersible and DP paediatric arms at any of the time
points assessed, despite the difference in half-life bet-
ween lumefantrine (four to six days) [25,26] and pipera-
quine (two to three weeks) [27]. This may be due to the
intensity of transmission in this region.
The current study was conducted in children aged be-
tween six and 59 months in the meso-endemic area of
Kenya, where the malaria prevalence rate has increased
from 4% in 2007 to 8% in 2010 [28]. This high-risk
population has less likelihood of semi-immunity, andTable 4 Biological parameter changes during treatment
Parameter AL dispersible
N Mean change (95% C
Haemoglobin (g/dl) 178 1.6 (1.3 to 1.9)
White blood cells (X103/μL) 178 −0.8 (−1.5 to −0.1)
Platelets (X103/μL) 178 88.5 (74.1 to 102.8)
Red blood cells (X106/μL) 178 0.6 (0.4 to 0.8)
Neutrophils (%) 178 −14.4 (−17.2 to −11.6)
Lymphocytes (%) 178 14.4 (11.3 to 17.4)
Eosinophils (%) 178 −0.2 (−0.7 to 0.2)
Basophils (%) 177 −0.02 (−0.10 to 0.07)
Monocytes (%) 177 −0.4 (−0.89 to 0.06)
CI = confidence interval.
A negative value indicates a decrease in day 28 values, on average compared to ba
*p-value from ANCOVA test of difference at day 28 between arms adjusting for bashence the efficacy detected was not greatly influenced by
previous exposure to malaria [29].
With widespread adoption and scaled-up use of AL
dispersible and other ACT in many sub-Saharan African
countries, there is a risk of development of resistance;
however, so far parasite resistance has not been reported
in this region. In the present study, the majority of the
children had parasite clearance within 48 hours with AL
and DP and the parasite clearance rate reported here
was similar to previously reported rates [30,31]. This
demonstrates that the P. falciparum parasites in this re-
gion are still sensitive to artemisinin derivatives, unlike
in some regions of Southeast Asia where delayed re-
sponse to ACT has been reported [32,33]. This study
builds on evidence for clinical practice in Kenya and
sub-Saharan African countries that AL dispersible re-
mains efficacious as a first-line treatment for uncompli-
cated P. falciparum malaria.
Overall, both drugs were well tolerated by children. There
was a comparable occurrence of AEs in the AL dispersible
and DP pediatric arms, with the most commonly reported
AEs being malaria and cough, in line with the previously
published data [23,34-38]. No deaths were reported. One
SAE was reported in the AL dispersible arm (severe mal-
aria) and this was not considered to be related to the study
drug. No discontinuations due to the study drug were ob-
served. One limitation of the study was that it was not
blinded and there was therefore potential for bias regarding
tolerability and efficacy assessments. This was mitigated
with a blinded randomization procedure and with the par-
ents being blinded regarding the assigned drug.
Both of the ACT studied here are fixed-dose formula-
tions. AL dispersible is administered twice daily for three
days, whereas DP paediatric is administered once daily for
three days. AL dispersible should be administered with food
or milk [16] to enhance lumefantrine absorption. Although
the above facts might suggest that better treatmentDP paediatric p-value*
I) N Mean change (95% CI)
185 1.7 (1.4 to 1.9) 0.134
185 −0.5 (−1.0 to 0.3) 0.869
185 88.3 (76.2 to 102.8) 0.926
185 0.7 (0.6 to 0.9) 0.394
185 −16.6 (−19.4 to −13.9) 0.857
185 18.8 (16.0 to 21.6) 0.081
185 - -
185 −0.08 (−0.19 to 0.03) 0.309
185 −0.78 (−1.54 to −0.02) 0.633
seline.
eline values.
Table 5 Drug questionnaire response
AL dispersible N = 126 DP paediatric N = 124 p-value*
Regimen, median number of tablets required 6 4
Pack available for survey, n (%) 117 (93.6) 107 (85.6) 0.089
Acceptability and comprehension
Health worker explained how to administer drug, n (%) 124 (99.2) 122 (98.4) 0.684
Health worker used pictures to explain how to administer drug, n (%) 123 (99.2) 123 (99.2) 0.321
Pictures helped in understanding how to administer, n (%) 124 (99.2) 124 (99.2) 0.159
Difficulty/Ease of using drug
0.001
Very difficult, n (%) 0 3 (2.4)
Difficult, n (%) 2 (1.6) 10 (8.1)
Acceptable, n (%) 19 (15.2) 28 (22.6)
Simple, n (%) 85 (68.0) 56 (45.2)
Very simple, n (%) 18 (14.4) 27 (21.8)
Difficulty/Ease of using drug A compared to B
0.007
Very difficult, n (%) - -
Difficult, n (%) 3 (2.4) 11 (8.9)
Acceptable, n (%) 25 (20.0) 28 (22.6)
Simple, n (%) 82 (65.6) 59 (47.6)
Very simple, n (%) 14 (11.2) 26 (21.0)
Taste of medicine for child
0.001
Not at all, n (%) 0 4 (3.2)
Not very much, n (%) 11 (8.8) 24 (19.4)
Acceptable, n (%) 23 (18.4) 25 (20.2)
Liked it, n (%) 80 (64.0) 50 (40.3)
Liked it very much, n (%) 10 (8.0) 20 (16.1)
Liquid for dissolving tablet
0.301Water, n (%) 119 (95.4) 115 (92.7)
Other, n (%) 6 (4.6) 10 (7.3)
Drug taken with a meal, n (%) 118 (94.4) 110 (89.4)
Prefer drug given as
0.025
Syrup, n (%) 21 (16.8) 36 (29.5)
Whole tablet which dissolves in small volume of water/milk, n (%) 96 (76.8) 76 (62.3)
Injection, n (%) 2 (1.6) 7 (5.7)
Other, n (%) 6 (4.8) 8 (6.4)
Prefer other anti-malarias, n (%) 4 (3.2) 5 (4.0)
Perceived adverse drug reactions
Anything unusual after medication given, n (%) 4 (3.2) 1 (0.8)
Concomitant medication given, n (%) 3 (2.6) 2 (1.9)
Adverse reaction solicited, n (%) 2 (1.7) 1 (0.9)
Caretaker reported ADR to health worker, n (%) 2 (1.7) 1 (0.9)
ADR/SAE completed based on events seriousness, n (%) 1 (0.9) 1 (0.9)
AL: artemether-lumefantrine; DP: dihydroartemisinin-piperaquine.
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http://www.malariajournal.com/content/13/1/33acceptability and tolerability may be observed with DP
paediatric compared with AL dispersible, according to the
survey conducted in this study, acceptability and tolerabilityto treatment regimen was in fact higher in the AL dispers-
ible arm. More respondents considered AL dispersible sim-
ple to use and to have a better taste. Most ACT need to be
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http://www.malariajournal.com/content/13/1/33crushed and mixed with water or food. Since they have a
bitter taste, children can expectorate the medicine and this
may result in them not receiving the full therapeutic dose.
With its palatable flavour (‘liked’ or ‘liked very much’ by
72% of respondents), AL dispersible may enhance adhe-
rence and improve therapeutic outcomes in children
[39,40]. Moreover, it has been demonstrated that with the
content of standard African diets or milk optimal efficacy is
achieved with fixed-dose AL (Coartem) [16]. Oral bioaval-
ability of AL was shown to increase by 108% when a nor-
mal meal was taken close to AL dosing compared to a
fasting condition. Another finding of note in the accepta-
bility and tolerability survey was the strong preference
expressed for whole tablets, which dissolve in a small
volume of water/milk over syrup formulations. Previous re-
search has shown that dry powder formulations intended
for suspension in water are more often substandard, relative
to tablets [41], and may contain ineffective or incorrect
amounts of preservatives [42]. DP may be a good alter-
native to AL or may have use as rescue medication, and
advice should be given regarding the policy and clinical
practice for deployment of DP as second-line therapy in the
treatment of uncomplicated falciparum malaria in Kenya.
Conclusions
AL is efficacious and remains the first-line treatment op-
tion for uncomplicated falciparum malaria. Both drugs
were well tolerated by children. DP has proved to be as
efficacious as AL. Parasites in this area remain sensitive
to artemisinins.
Competing interests
None of the authors has affiliation to the manufacturers, and they have
declared that they have no competing interests. The drugs were donated by
the respective manufacturers.
Authors’ contributions
BRO designed the research (development of overall research plan and study
oversight), conducted the research (data collection and patient care), and
analysed the data. KO collected data, was involved in patient care and data
analysis. NK collected data and was involved in patient care. JO, GO and CO
designed the research plan, collected, and analysed the data. LO, DO and
WA designed the research. FE and JJ carried out the molecular studies. RO
and EJ designed the study and analysed the data. All authors participated in
the preparation of the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This work has been published with the permission of the Director of the
Kenya Medical Research Institute. This study was funded by Division of
Malaria Control of the Ministry of Health, Kenya through support from WHO
country office and DFID. The authors thank the patients and their parents
who took part and the staff at the Ombeyi Dispensary. The authors would
like to thank Ubhayabharathi Gurunath, professional medical writer (Novartis)
for editorial support.
Author details
1Centre for Clinical Research, Kenya Medical Research Institute, Kisumu,
Kenya. 2Walter Reed Project/Centre for Clinical Research, Kenya Medical
Research Institute, Kisumu, Kenya. 3Centre for Global Health Research, Kenya
Medical Research Institute, Kisumu, Kenya. 4Drugs for Neglected Disease
Initiative, Kenya Medical Research Institute, Nairobi, Kenya. 5Center for GlobalHealth, University of New Mexico, New Mexico, USA. 6Department of Disease
Control and Prevention, Ministry of Public Health and Sanitation, Nairobi,
Kenya. 7Division of Malaria Control, Ministry of Public Health and Sanitation,
Nairobi, Kenya.
Received: 13 August 2013 Accepted: 7 January 2014
Published: 28 January 2014
References
1. World Malaria Report: World Malaria Report; 2011. http://www.who.int/
entity/malaria/world_malaria_report_2011/9789241564403_eng.pdf.
2. World Health Organization: Guidelines for the Treatment of Malaria. 2nd
edition; 2010. http://www.who.int/malaria/publications/atoz/
9789241547925/en/index.html.
3. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F,
Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K,
Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N,
Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum
malaria. N Engl J Med 2009, 361:455–67.
4. Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium, Noedl H,
Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM: Evidence of
artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008,
359:2619–20.
5. Noedl H, Socheat D, Satimai W: Artemisinin-resistant malaria in Asia.
N Engl J Med 2009, 361:540–541.
6. Rønn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC: High level
of resistance of Plasmodium falciparum to sulfadoxine–pyrimethamine in
children in Tanzania. Trans R Soc Trop Med Hyg 1996, 90:179–81.
7. International Artemisinin Study Group, Adjuik M, Babiker A, Garner P, Olliaro
P, Taylor W, White N: Artesunate combinations for treatment of malaria:
meta–analysis. Lancet 2004, 363:9–17.
8. Kokwaro G, Mwai L, Nzila A: Artemether/lumefantrine in the treatment of
uncomplicated falciparum malaria. Expert Opin Pharmacother 2007,
8:75–94.
9. Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, Pinder
M, Doherty T, Sutherland C, Walraven G, Milligan P: Artesunate reduces but
does not prevent posttreatment transmission of Plasmodium falciparum
to Anopheles gambiae. J Infect Dis 2001, 183:1254–59.
10. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L,
Chongsuphajaisiddhi T, White NJ: Effects of artemisinin derivatives on
malaria transmissibility. Lancet 1996, 347:1654–58.
11. Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, Walter V,
Beck HP, Marrast AC, Cousin C, Rosenthal PJ: Efficacy and safety of
artemether lumefantrine in the treatment of acute uncomplicated
Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg
2011, 85:793–804.
12. Hamed K, Grueninger H: Coartem®: A decade of patient–centric malaria
management. Expert Rev Anti Ther 2012, 10:645–659.
13. Hamel MJ, Adazu K, Obor D, Sewe M, Vulule J, Williamson JM, Slutsker L,
Feikin DR, Laserson KF: A reversal in reductions of child mortality in
western Kenya, 2003–2009. Am J Trop Med Hyg 2011, 85:597–605.
14. Manyando C, Mkandawire R, Puma L, Sinkala M, Mpabalwani E, Njunju E,
Gomes M, Ribeiro I, Walter V, Virtanen M, Schlienger R, Cousin M, Chipimo
M, Sullivan FM: Safety of artemether-lumefantrine in pregnant women
with malaria: results of a prospective cohort study in Zambia. Malar J
2010, 9:249.
15. Abdulla S, Sagara I, Borrmann S, D'Alessandro U, González R, Hamel M,
Ogutu B, Mårtensson A, Lyimo J, Maiga H, Sasi P, Nahum A, Bassat Q, Juma
E, Otieno L, Björkman A, Beck HP, Andriano K, Cousin M, Lefèvre G, Ubben
D, Premji Z: Efficacy and safety of artemether-lumefantrine dispersible
tablets compared with crushed commercial tablets in African infants and
children with uncomplicated malaria: a randomised, single-blind, multi-
centre trial. Lancet 2008, 372:1819–1827.
16. Premji ZG, Abdulla S, Ogutu B, Ndong A, Falade CO, Sagara I, Mulure N,
Nwaiwu O, Kokwaro G: The content of African diets is adequate to
achieve optimal efficacy with fixed–dose artemether-lumefantrine: a
review of the evidence. Malar J 2008, 7:244.
17. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB,
Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG: Artemisinin com-
bination therapies for treatment of uncomplicated malaria in Uganda.
PLoS Clin Trials 2006, 1:e7.
Ogutu et al. Malaria Journal 2014, 13:33 Page 10 of 10
http://www.malariajournal.com/content/13/1/3318. Janssens B, van Herp M, Goubert L, Chan S, Uong S, Nong S, Socheat D,
Brockman A, Ashley EA, Van Damme W: A randomized open study to
assess the efficacy and tolerability of dihydroartemisinin-piperaquine for
the treatment of uncomplicated falciparum malaria in Cambodia.
Trop Med Int Health 2007, 12:251–259.
19. Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba
D, Mulenga M, Ubben D, D’Alessandro U: Safety and efficacy of
dihydroartemisinin-piperaquine versus Artemether-lumefantrine in the
treatment of uncomplicated Plasmodium falciparum malaria in Zambian
children. Malar J 2011, 10:50.
20. ICH Harmonized Tripartite guideline: Guidelines for Good Clinical practiceE6
(R1);1996. Current Step 4 version. http://www.ich.org/fileadmin/
Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/
E6_R1__Guideline.pdf.
21. World Health Organization, Communicable Diseases Cluster: Severe
falciparum malaria. Trans R Soc Trop Med Hyg 2000, 94(1):S1–90.
22. World Health Organization: Assessment and monitoring of antimalarial drug
efficacy for the treatment of uncomplicated falciparum malaria. Geneva:
WHO. WHO/HTM/RBM/2003.50 2003.
23. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG,
Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire–Mangen F,
Dorsey G: Artemether-lumefantrine versus dihydroartemisinin-
piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials
2007, 2:e20.
24. Wabwire-Mangen F, Bukirwa H, Rwakimari JB, Staedke SG, Rosenthal PJ,
Lugemwa M, Yeka A, Dorsey G, Kamya MR, Talisuna A: Artemether-
lumefantrine versus dihydroartemisinin-piperaquine for treating
uncomplicated malaria: a randomized trial to guide policy in Uganda.
PLoS One 2008, 3:e2390.
25. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ:
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol)
in acute falciparum malaria. Antimicrob Agents Chemother 2000,
44:697–704.
26. Product monograph; 2010. [http://www.coartem.com/product–monograph.
htm] Coartem® –artemether/lumefantrine.
27. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C,
Socheat D: Population pharmacokinetics of piperaquine in adults and
children with uncomplicated falciparum or vivax malaria. Br J Clin
Pharmacol 2004, 57:253–262.
28. Badu K, Afrane YA, Larbi J, Stewart VA, Waitumbi J, Angov E, Ong'echa JM,
Perkins DJ, Zhou G, Githeko A, Yan G: Marked variation in MSP-119 anti-
body responses to malaria in western Kenyan highlands. BMC Infect Dis
2012, 12:50.
29. Kenya malaria indicator survey (DoMC); 2010. http://measuredhs.com/pubs/
pdf/MIS7/MIS7.pdf.
30. Elamin SB, Awad AI, Eltayeb IB, Elmardi KA, Hassan AH, Mohamed AO,
Malik EM, Mohamad TA: Descriptive study on the efficacy of artemether-
lumefantrine in the treatment of uncomplicated Plasmodium falciparum
malaria in Sudan. Eur J Clin Pharmacol 2010, 66:231–237.
31. Juma EA, Obonyo CO, Akhwale WS, Ogutu BR: A randomized, open–label,
comparative efficacy trial of Artemether-lumefantrine suspension versus
Artemether-lumefantrine tablets for treatment of uncomplicated
Plasmodium falciparum malaria in children in western Kenya. Malar J
2008, 7:262.
32. Resistance to artemisinin derivatives along the Thai–Cambodian border.
Wkly Epidemiol Rec 2007, 82:360.
33. WHO: The status of drug–resistant malaria along the Thailand–Myanmar
border. http://www.who.int/malaria/publications/atoz/
drug_resistance_myanmar_thailand_border_may_2012.pdf.
34. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Kamya MR,
Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G: Artemether-
lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria:
a longitudinal, randomized trial in young Ugandan children.
Clin Infect Dis 2009, 49:1629–1637.
35. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F,
Ebsworth EP, Anstey NM, Tjitra E, Price RN: Two fixed–dose artemisinin
combinations for drug–resistant falciparum and vivax malaria in Papua,
Indonesia: an open–label randomised comparison. Lancet 2007,
369:757–765.
36. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, Nambozi
M, Valéa I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A,D'Alessandro U: Dihydroartemisinin-piperaquine and artemether-
lumefantrine for treating uncomplicated malaria in African children: a
randomised, non-inferiority trial. PLoS One 2009, 4:e7871.
37. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F, Dorsey G, Janssens B,
Mayxay M, Newton P, Singhasivanon P, Stepniewska K, White NJ, Nosten F:
Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria:
a prospective multi-centre individual patient data analysis. PLoS One 2009,
4:e6358.
38. Myint HY, Ashley EA, Day NP, Nosten F, White NJ: Efficacy and safety of
dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 2007,
101:858–866.
39. Abdulla S, Sagara I: Dispersible formulation of artemether/lumefantrine:
specifically developed for infants and young children. Malar J 2009,
8(1):S7.
40. Makanga M, Krudsood S: The clinical efficacy of artemether/lumefantrine
(Coartem). Malar J 2009, 8(1):S5.
41. Atemnkeng MA, De Cock K, Plaizier-Vercammen J: Quality control of active
ingredients in artemisinin-derivative antimalarials within Kenya and DR
Congo. Trop Med Int Health 2007, 12:68–74.
42. Atemnkeng MA, De Cock K, Plaizier-Vercammen J: Post-marketing assessment
of content and efficacy of preservatives in artemisinin-derived antimalarial
dry suspensions for paediatric use. Malar J 2007, 6:12.
doi:10.1186/1475-2875-13-33
Cite this article as: Ogutu et al.: Efficacy and safety of artemether-
lumefantrine and dihydroartemisinin-piperaquine in the treatment of
uncomplicated Plasmodium falciparum malaria in Kenyan children aged
less than five years: results of an open-label, randomized, single-centre
study. Malaria Journal 2014 13:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
